Andres Sheppard at Cantor Fitzgerald said in an interview that he saw a couple of positives in the report that may have prompted investors to look past the miss. "I personally think the biggest ...

Wednesday, January 29, 2025 - In a recent industry report focused on Biotechnology stocks, particularly those innovating in neurology and psychiatry, Cantor Fitzgerald highlighted a positive ...

On Wednesday, Cantor Fitzgerald initiated coverage on Galaxy Digital Holdings Ltd (TSX:GLXY:CN) (OTC: BRPHF), assigning an Overweight rating to the company's stock with a price target of Cdn$44.00.

On Wednesday, Cantor Fitzgerald reaffirmed its Overweight rating on Microsoft stock (NASDAQ:MSFT), maintaining a price target of $509.00. The firm's analyst, Thomas Blakey, provided insights ahead of ...

A slew of space stocks have skyrocketed following the inauguration of President Trump, boosted by his vow to champion American space exploration during his administration. Set against this ...

Cantor Fitzgerald has a convertible bond with Tether, incoming Commerce Secretary Howard Lutnick said at his confirmation hearing, confirming previous reporting by The Wall Street Journal that ...

This prediction is currently active. With a performance of -5.93%, the BUY prediction by Cantor_Fitzgerald is trending in the wrong direction. This prediction currently runs until 29.01.26. The ...

What does this Advisor Specialize in? Find a financial advisor who specializes in the area of expertise you require. It's important to find an advisor who can help you approach your personal and ...

Cantor Fitzgerald assumed coverage of Cidara Therapeutics (CDTX) with an Overweight rating. Cidara’s lead asset CD388, an anti-viral that targets neuraminidase, an essential surface receptor ...

Palantir Technologies Inc. (NASDAQ:PLTR – Free Report) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings estimates for Palantir Technologies in a note issued to ...

Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) – Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Fate Therapeutics in a report issued on Tuesday ...